📣 Help Shape the Future of UKRI's Gateway to Research (GtR)

We're improving UKRI's Gateway to Research and are seeking your input! If you would be interested in being interviewed about the improvements we're making and to have your say about how we can make GtR more user-friendly, impactful, and effective for the Research and Innovation community, please email gateway@ukri.org.

Ruxolitinib-induced defects in DNA repair cause sensitivity to PARP inhibitors in myeloproliferative neoplasms. (2017)

First Author: Nieborowska-Skorska M

Attributed to: Wellcome Trust MRC Cambridge Stem Cell Institute funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1182/blood-2017-05-784942

PubMed Identifier: 29042365

Publication URI: http://europepmc.org/abstract/MED/29042365

Type: Journal Article/Review

Volume: 130

Parent Publication: Blood

Issue: 26

ISSN: 0006-4971